semaglutide advertising Creative Social Media Ad for The Truth About Semaglutide -

They can be safe when prescribed by a licensed healthcare provider

GLP-1 drugs amplify these natural signals, helping you feel full longer and reducing those pesky food cravings that can derail your weight loss efforts

BMI 25 to 30 (overweight) People starting in the overweight range can expect moderate but meaningful weight loss

ButlerMerrill Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$10M$2.4B$3-50M$1-341MBarrett RichterMorgan Stanley Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$5M$4.8B$8-50M$5-15MJohn ShuhdaMerrill Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$5M$815M$6-30M$3-25MAlex SmithCresset Asset ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$25M$807M$25-500M$10-100MBrooks Hays-SlateCresset Asset ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$25M$807M$25M-1B$10-100MAndrew BaumgartnerUBS Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$10M$3.6B$10-50M$5-30MMindy FishelRaymond James & AssociatesSan FranciscoCalifornia - San Francisco (Private Wealth)$2M$1.3B$7.5-15M$10-20MProfile SpotlightSean BricmontMorgan Stanley Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$5M$2.6B$20-135M$575K-84MMichael JankiewiczUBS Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$2M$1.8B$10-50M$4-30MDaphne ChiUBS Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$2M$593M$5-25M$1-10MMichelle EversmanAspiriantSan FranciscoCalifornia - San Francisco (Private Wealth)$1.5M$16.1B$1.5-500M$1.5-10MRob SullivanWells Fargo AdvisorsSan FranciscoCalifornia - San Francisco (Private Wealth)$800K$3.2B$2-100M$1-3MTim ShibataMerrill Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$250K$39.6B$10-500M$5-200MDonald TrabertUBS Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$5M$1.4B$13-110M$5-50MScott BuoyMerrill Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$10M$1.3B$15-125M$10-75MLaura WardWilliam BlairSan FranciscoCalifornia - San Francisco (Private Wealth)$4M$922M$5-100M$4-50MSean EdringtonUBS Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$5M$1.4B$10M-2B$5-500MMarco SalernoMorgan Stanley Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$10M$2.2B$10-75M$10-150MChristopher GarciaMerrill Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$250K$39.6B$10-500M$5-200MMatt GoldbergMerrill Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$250K$39.6B$10-500M$5-200MChris SercuMerrill Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$250K$39.6B$10-500M$5-200MMark HoweMorgan Stanley Private Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$10M$5B$60-100M$2-60MMaggie YumUBS Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$3M$2.2B$3-15M$5-30MEmmie YangUBS Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$2M$2.2B$5-50M$3-10MMichael Grinnell IIMerrill Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$1M$1.1B$6-30M$2-10MPaul MinasianMorgan Stanley Wealth ManagementSan FranciscoCalifornia - San Francisco (Private Wealth)$2M$1B$4-20M$1.5-20MProfile SpotlightBrian BrociousJ.P

Switching from Injectable to Oral# Recommendation : Orforglipron Reason : ATTAIN-MAINTAIN showed that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their previously achieved weight loss, validating oral step-down therapy

Here are strategies to ensure clarity and avoid misinformation: Use neutral language: Emphasize that research is ongoing and that any effects on alcohol use are not guaranteed